Subscribe
shutterstock_2102832088_irina_anosova
Irina Anosova / Shutterstock.com
16 November 2022Big PharmaStaff Writer

Big pharma steps up access, but uneven progress made: report

Licensing of COVID-19 treatments has shifted to include other medicines and treatment areas | World’s largest pharma companies still “consistently overlook the poorest countries” | Report offers strategy to improve access.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Canada delivers landmark ruling in favour of big pharma
22 February 2022   The Quebec Court of Appeal in Canada has ruled that the 2019 amendments to the Patented Medicines Regulations, governing the country’s Patented Medicine Prices Review Board (PMPRB) are partially invalid.
Big Pharma
Gilenya injunction bid: big pharma takeaways
21 June 2022   The England and Wales Patent Court affirmed its power to grant injunctions for pre-grant patents—but not for Novartis, explains Azadeh Vahdat of EIP.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Americas
Canada delivers landmark ruling in favour of big pharma
22 February 2022   The Quebec Court of Appeal in Canada has ruled that the 2019 amendments to the Patented Medicines Regulations, governing the country’s Patented Medicine Prices Review Board (PMPRB) are partially invalid.
Big Pharma
Gilenya injunction bid: big pharma takeaways
21 June 2022   The England and Wales Patent Court affirmed its power to grant injunctions for pre-grant patents—but not for Novartis, explains Azadeh Vahdat of EIP.

More on this story

Americas
Canada delivers landmark ruling in favour of big pharma
22 February 2022   The Quebec Court of Appeal in Canada has ruled that the 2019 amendments to the Patented Medicines Regulations, governing the country’s Patented Medicine Prices Review Board (PMPRB) are partially invalid.
Big Pharma
Gilenya injunction bid: big pharma takeaways
21 June 2022   The England and Wales Patent Court affirmed its power to grant injunctions for pre-grant patents—but not for Novartis, explains Azadeh Vahdat of EIP.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages